The potential of repurposed drug treatments for severe mental illness
Drug repurposing is potentially cost-effective, low risk, and necessary in psychiatric drug development. The availability of large, routine data sets provides the opportunity to evaluate the potential for currently used medication to benefit people with serious mental illness. Using linked Swedish register data we set out to determine whether hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type calcium channel antagonists, and biguanides are associated with reduced psychiatric hospitalisation and self-harm in individuals with severe mental illness.
Date:
26 November 2019, 9:30 (Tuesday, 7th week, Michaelmas 2019)
Venue:
Warneford Hospital, Headington OX3 7JX
Venue Details:
Seminar Room, Department of Psychiatry
Speaker:
Dr Joseph Hayes (University College London)
Organising department:
Department of Psychiatry
Organiser:
Elizabeth Thomas (University of Oxford)
Part of:
Psychiatry Seminars
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Elizabeth Thomas
